What is HC Wainwright’s Forecast for Innoviva Q3 Earnings?

Innoviva, Inc. (NASDAQ:INVA) – HC Wainwright lowered their Q3 2026 earnings per share (EPS) estimates for Innoviva in a research report issued on Monday, June 22nd. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will earn $0.50 per share for the quarter, down from their previous forecast of $0.51. HC Wainwright currently has a “Buy” rating and a $46.00 target price on the stock. The consensus estimate for Innoviva’s current full-year earnings is $2.23 per share. HC Wainwright also issued estimates for Innoviva’s FY2026 earnings at $2.20 EPS.

Other research analysts have also recently issued reports about the stock. Wall Street Zen upgraded shares of Innoviva from a “hold” rating to a “buy” rating in a report on Saturday, June 6th. Weiss Ratings restated a “buy (b)” rating on shares of Innoviva in a report on Friday, March 27th. Finally, BTIG Research restated a “buy” rating and issued a $42.00 price target on shares of Innoviva in a research report on Monday. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Innoviva currently has an average rating of “Moderate Buy” and a consensus price target of $36.20.

Innoviva Price Performance

NASDAQ INVA opened at $23.57 on Wednesday. The company has a current ratio of 21.13, a quick ratio of 20.07 and a debt-to-equity ratio of 0.19. Innoviva has a 1 year low of $16.52 and a 1 year high of $25.15. The company has a market cap of $1.74 billion, a PE ratio of 3.92 and a beta of 0.35. The stock’s 50-day moving average price is $22.75 and its two-hundred day moving average price is $21.86.

Innoviva (NASDAQ:INVA) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.01. The business had revenue of $97.99 million during the quarter, compared to analyst estimates of $101.57 million. Innoviva had a return on equity of 33.33% and a net margin of 119.89%.

Institutional Investors Weigh In On Innoviva

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in Innoviva by 11.6% during the 4th quarter. Vanguard Group Inc. now owns 7,917,103 shares of the biotechnology company’s stock valued at $158,263,000 after acquiring an additional 819,757 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Innoviva by 1.7% in the first quarter. Dimensional Fund Advisors LP now owns 4,436,427 shares of the biotechnology company’s stock worth $103,366,000 after purchasing an additional 76,026 shares in the last quarter. State Street Corp lifted its position in shares of Innoviva by 9.4% in the fourth quarter. State Street Corp now owns 2,796,820 shares of the biotechnology company’s stock worth $55,908,000 after purchasing an additional 239,848 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in shares of Innoviva by 38.1% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,358,633 shares of the biotechnology company’s stock worth $43,045,000 after purchasing an additional 650,151 shares in the last quarter. Finally, American Century Companies Inc. boosted its holdings in shares of Innoviva by 13.8% during the third quarter. American Century Companies Inc. now owns 2,351,006 shares of the biotechnology company’s stock worth $42,906,000 after purchasing an additional 284,253 shares during the period. 99.12% of the stock is owned by hedge funds and other institutional investors.

Innoviva News Roundup

Here are the key news stories impacting Innoviva this week:

• Positive Sentiment: BTIG Research reaffirmed its Buy rating on Innoviva and set a $42 price target, reinforcing a bullish longer-term view on the shares.
• Positive Sentiment: Innoviva Specialty Therapeutics partnered with Dr. Reddy’s to expand XACDURO access internationally, which could broaden the product’s reach and support future revenue growth. Article: Innoviva Specialty Therapeutics (INVA) Partners With Dr. Reddy’s to Expand XACDURO Access Internationally
• Neutral Sentiment: HC Wainwright kept a Buy rating and $46 price target, but trimmed estimates across multiple periods, including Q3 2026 EPS to $0.50 from $0.51 and FY2026 EPS to $2.20 from $2.23, signaling only modest near-term caution rather than a major change in outlook.
• Neutral Sentiment: The same firm also lowered longer-dated projections slightly, including Q4 2026, Q1 2027, Q2 2027, Q3 2027, Q4 2027, and FY2027 EPS, but the revisions were small and still accompanied by an upbeat rating.

Innoviva Company Profile

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.